(A61K9/127)

Pharmaceutical niosomal gel based on n-hydroxy-2-(2-(naphtalene-2-yl)-1h-indole-3-yl)-2-phenylacetamide with anti-tumour activity to glioblastoma // 2627449
FIELD: pharmacology.SUBSTANCE: composition is a niosomal gel containing the niosome-encapsulated synthesized N-hydroxy-2-(2-(naphthalene-2-yl)-1H-indole-3-yl)-2-phenylacetamide.EFFECT: implementation of the invention allows to increase the efficiency of antitumor substance transport into the target cells, thereby increasing the therapeutic effect of the niosomal gel for the treatment of glioblastoma.1 tbl, 2 dwg

Sustainable crystalline modifications of chloride dotap // 2627354
FIELD: chemistry.SUBSTANCE: invention relates to a method of manufacturing crystalline form of chloride (2R, S)-, (2S)- or (2R)-DOTAP (N, N, N-trimethyl-2,3-bis [[(9Z) -1-oxo -9-octadecenyl] oxy]-1-propanamide chloride). The process comprises crystallization chloride (2R, S)-, (2S)- or (2R)-DOTAP of one or more aprotic solvents, wherein the crystallisation takes place by cooling slowly from 35°C to -12°C for constituting 12 hours, or by slowly cooling from a temperature lower than the time period 35°. C over a period of time ranging from 10 to 50 parts crystalline chloride (2R, S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.6, 19.5, 20.2, 21.5 and 25.2; or 2 theta values, comprising at least the values of 6.5, 12.6, 13.4, 19.5, 20.2, 21.5, 25.2 and 29.8; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 1. Crystalline chloride (2S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.8, 19.5, 19.8, 20.2 and 21.6; 2 theta values, comprising at least the values of 6.5, 12.8, 19.5, 19.8, 20.2, 20.7, 21.6 and 25.3; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 2. Crystalline chloride (2S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.8, 19.5, 19.8, 20.2 and 21.6; 2 theta values, comprising at least the values of 6.5, 12.8, 19.5, 19.8, 20.2, 20.7, 21.6 and 25.3; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 3. X-ray powder diffractometry was carried out using Cu as a radiation source.EFFECT: proposed method allows to obtain crystalline forms of chloride with improved stability and purity.8 cl, 12 dwg, 5 tbl, 5 ex
ethod for production of immobilzed bilayer vesicles // 2627157
FIELD: biotechnology.SUBSTANCE: carrier containing a covalently bound polymer and a surface negative charge is treated with a suspension of cationic bilayer vesicles in a water-containing medium. Micellar particles obtained by aggregation in a water-containing medium of a block copolymer consisting of polylactide and polyoxyethylene are used as a carrier. Vesicles consisting of at least one cationic lipid or a mixture of at least one cationic lipid and at least one electrically neutral lipid are used as vesicles. At that, at least two vesicles shall be per one carrier particle.EFFECT: invention simplifies the production of immobilized bilayer vesicles and expands the arsenal of technical means that can be used to produce immobilized bilayer vesicles.11 ex

Ophthalmic composition // 2625301
FIELD: pharmacology.SUBSTANCE: ophthalmic composition contains a formula compound, where the values for R1 and R2 groups are given in the claims, and an ophthalmologically acceptable carrier. The invention also relates to a method for dry eye treatment, comprising local administration of a therapeutically effective amount of the ophthalmic composition to the eye of the subject in need.EFFECT: increased efficiency.20 cl, 6 dwg, 6 ex
Agent with isoniazid-containing liposomes // 2622755
FIELD: pharmacology.SUBSTANCE: capsules for oral use comprise liposomes prepared by mixing egg lecithin, PEG 2000 and Tween-80 at the ratio of 6:2:1 at a temperature of 40°C, followed by hydration, encapsulated for oral use, wherein liposomes comprise isoniazid as an active agent in the following ratio of liposome components, g per 1 capsule: isoniazid - 0.3; a mixture of phospholipid, PEG 2000 and Tween-80 - 0.22. Number 0 capsules with a diameter of 7.65 mm, length of 21.7 mm, filling volume of 0.68 ml are additionally used.EFFECT: agent has antiphthisic effect, as well as constant-rate release of active agents and pronounced prolonged action, it is convenient for using by patients themselves.3 tbl, 3 ex

Application of liposomal dihydroquercetin emulsion "flamena" for treatment of chronic endometritis with autoimmune disorders in case of infertility // 2622024
FIELD: medicine.SUBSTANCE: effective treatment method represents a complex therapy that includes enzyme therapy, physical therapy, hormone therapy, as well as application of liposomal dihydroquercetin emulsion "Flamena".EFFECT: application of the method allows to achieve pregnancy for more than 90 percent of patients.3 cl, 3 dwg, 3 tbl, 3 ex
ethod for liposomes obtaining // 2621145
FIELD: biotechnology.SUBSTANCE: invention is a method for liposomes obtaining and is characterized by evaporation of a 1% solution of lecithin in ethyl alcohol in a rotary IKA RV10 control evaporator at a water bath temperature of 60°C, resulting in lipid film formation on the evaporation flask wall, then a centimolar Sodium phosphate buffer pH 7.4 was added in a volume equal to the volume of the lecithin solution in ethyl alcohol, stirred for 1 minute, then the resulting solution was sonicated for 15 minutes.EFFECT: method allows to obtain a monodisperse homogeneous system with a particle size of 59,9 to 106,2 nm.2 tbl
Liposome composition for inflammatory joint diseases relief // 2611998
FIELD: pharmacy.SUBSTANCE: invention is represented by a liposome composition for inflammatory joint diseases relief, comprising dipalmitoylphosphatidylcholine, cholesterol, hydrocortisone acetate, prednisolone hemisuccinate and saline, at that, the components are in a certain ratio, in g.EFFECT: high anti-inflammatory effect and rapid beneficial effect.2 ex

Liposomal composition for application in peritoneal dialysis // 2609860
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, namely to a liposome composition for application in peritoneal dialysis for patients with from endogenous or exogenous intoxication, wherein the pH inside the liposomes is characterized by the pH in the peritoneal cavity and is preferably 1.5-4.0 or 9.0-10.0, and wherein the pH inside the liposomes results in formation of a charged toxin, incorporated into a liposome.EFFECT: invention provides detoxification by charged toxin capturing within liposomes.8 cl, 5 ex, 5 dwg
Enhanced immune response in bovine species // 2606855
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics and concerns an immunomodulator composition for treating bovine respiratory disease in cattle caused by Mannheimia haemolytica, which comprises a cationic liposome delivery vehicle and nucleic acid molecule, where nucleic acid molecule is a bacterially-derived non-coding DNA plasmid vector, produced in E.coli, containing 4242 base-pairs without a gene insert.EFFECT: invention provides a eliciting systemic, non-specific and antigen-specific immune responses in animals for protection against infectious respiratory disease.11 cl, 6 ex, 6 tbl, 27 dwg

Liposomal agent based on ubiquinol and preparation method thereof // 2605616
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, chemical-pharmaceutical and cosmetic industry, namely to method of producing liposomal form ubiquinol (reduced Coenzyme Q10), involving preparation of solution, containing mixture of phospholipid and sterol in weight ratio of 1:0.1-2 respectively, ubiquinol with weight ratio of ubiquinol to mixture of phospholipid and sterol equal to 1:1-4, respectively, and co-solvent in form of nonionic surfactant in ethanol, dispersion of obtained solution, containing lipid fraction, in aqueous medium containing cryoprotectant to obtain suspension of lipid vesicles with ubiqinol in them, homogenization of suspension of lipid vesicles and separation of liposomes with size no more than 220 nm with ubiquinol included therein, as well as to liposomal pharmaceutical and cosmetic compositions including liposomal form of ubiquinol obtained using said method.EFFECT: group of inventions provides higher bioavailability of coenzyme Q10, higher capture factor and stability of retention of coenzyme Q10 in liposomes.24 cl, 12 ex, 1 tbl, 1 dwg

Composition of vegetable origin in liposomal form // 2604133
FIELD: medicine.SUBSTANCE: invention relates to composition of vegetable origin with anti-inflammatory and throat softening action. Above composition is characterized by that it is liposome suspension and contains 0.1-0.5 wt% of eucalyptus extract, 0.1-0.5 wt% of echinacea extract, 1.5-3.0 wt% of sodium alginate or methyl cellulose, 0.1-1.0 wt% of mixture of nonionic SAS TWIN 20 and TWIN 80, taken at ratio of 1:4, 0.1-1.0 wt% of soya lecithin, 1.0-1.5 wt% of 96 % ethyl alcohol and water.EFFECT: invention provides suppression of inflammatory processes in throat and prevents onset of dry mouth, is characterized by prolonged action and high storage life.1 cl, 1 tbl, 3 ex

tb-c vaccine against asthma // 2602771
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and describes the agent for the treatment or prevention of an allergic condition. Agent, which is a liposome formulation comprising: (a) fragments of a Mycobacterium tuberculosis-complex (MTB-C) strain, (b) a liposome-forming agent, (b) 1 to 20 % sucrose. Also a liposomal agent is offered, where z-average particle size is equal to 150 nm or less, and a pharmaceutical composition comprising the specified agent.EFFECT: group of inventions provides the prevention and treatment of asthma in a mammal, attenuates airway hyperresponsiveness, eosinophilia level and lymphocytosis in the airways of sensitized animals, due to content of 1-20 % weight/volume of sucrose and specific particle size (less than 150 nm) in liposomal agent.32 cl, 15 dwg, 10 tbl, 10 ex

Agent with liposome containing albumin and propolis extract, exhibiting reparative activity in anaemias haemorrhagic // 2599505
FIELD: pharmaceutics.SUBSTANCE: invention relates to agent exhibiting reparative activity in haemorrhagic anaemia. Agent exhibiting reparative activity in hemorrhagic anaemia, containing 10% aqueous solution of albumin and 10% alcohol extract of propolis, included into liposomes, obtained by dissolving egg lecithin in a mixture of diethyl ether and chloroform in ratio 2:1, at temperature 37°C, with further distillation of organic layer to a dry residue, adding 10% aqueous solution of albumin and double processing mixture with ultrasound frequency 22 kHz and power of 500 W to formed emulsion is added 10% alcohol extract of propolis, wherein liposomes are enclosed in capsules for oral administration, in certain proportions.EFFECT: described above agent exhibits reparative, antioxidant, antispasmodic, anti-inflammatory, regenerative and antibacterial actions, as well as uniform release of active substances and manifested prolonged action, convenient for use by patients independently.3 cl, 1 dwg, 3 tbl, 3 ex

Composition of lipid vesicles and methods of application // 2595872
FIELD: medicine.SUBSTANCE: group of inventions relates to multilayer lipid vescible for delivery of therapeutic, prophylactic or diagnostic agent having a covalent crosslinks between lipid bilayers, wherein at least two lipid bilayers in multilayer lipid vesicle are covalently crosslinked to each other, as well as methods for production thereof, to methods of delivery of therapeutic, prophylactic or diagnostic agent and to pharmaceutical compositions containing such multilayer lipid vesicle.EFFECT: higher efficiency of encapsulation and stability of multilayer lipid vesicles.93 cl, 29 dwg, 3 tbl, 2 ex

Phospholipid-enriched vesicles bearing tissue factor having haemostatic activity and use thereof // 2595406
FIELD: biotechnology.SUBSTANCE: present invention relates to a method of improving procoagulant properties of tissue factor (TF) expressed in eukaryotic cells, and can be used in medicine. Modified tissue factor bearing microvesicle produced in accordance with present invention can be used as procoagulant agent for treating bleeding, wound healing and stimulating angiogenesis in tissues.EFFECT: invention improves procoagulant properties of tissue factor due to that obtained TF bearing microvesicle is generated from lipid membranes or their fragments of eukaryotic cells, in which tissue factor is expressed, as well as additional additive of negatively charged phospholipid.18 cl, 16 dwg, 2 tbl, 5 ex

Nanoparticle based, tumour-targeted delivery of medicinal agents // 2593367
FIELD: medicine. SUBSTANCE: group of inventions relates to aqueous tumour-targeted compositions of nanoparticles containing legumain-targeted lipid, containing a lipid component covalently bonded with binding legumain group, where binding legumain group includes legumain inhibitor type aza-Asn peptide with reactive part of presented formula (I): , as well as use thereof to treat expressing legumain tumour diseases. EFFECT: group of inventions eliminated risks associated with targeting using ligands, while providing effective agents for tumour-specific drug delivery. 16 cl, 11 dwg, 1 tbl, 6 ex

ethod for delivery of boron-containing preparations for boron neutron capture therapy // 2589822
FIELD: medicine.SUBSTANCE: invention relates to method for delivery of boron-containing preparations (10B) for boron neutron-capture therapy (BNCT), for delivery of boron-containing preparations into cells using pegylated liposomes. At that, when preparing liposomes, additionally luminescent dye of one colour is introduced into lipid part of liposomes, and luminescent dye of another colour - into aqueous part of liposomes, and control of delivery into cell is carried out by comparing images obtained in both colours with help of fixing device.EFFECT: invention provides high reliability of delivery of boron-containing preparations for BNCT inside tumour cells, and can enable both determination of intracellular boron concentration in different moments of time and determination of maximum intracellular boron concentration required to achieve maximum effect from BNCT.7 cl, 4 dwg

Liposomes with lipids, having preferred value of pka for rna delivery // 2589503
FIELD: medicine.SUBSTANCE: presented group of inventions relates to non-viral RNA delivery for immunisation. Disclosed is liposome for RNA in vivo delivery into cell of vertebrate animal with lipid bilayer containing lipid, having tertiary amine and value of pKa from 5.0 to 6.8, which encapsulates water core including RNA coding immunogen. Invention also discloses pharmaceutical composition containing said liposome, method of producing liposomes, method of inducing protective immune response in vertebrate animal and application of liposomes or pharmaceutical composition for inducing protective immune response in vertebrate animal.EFFECT: presented group of inventions provides effective in vivo delivery of RNA for induction of protective immune response in vertebrate animal.15 cl, 21 dwg, 18 tbl, 1 ex

ethod for preparing agent possessing lipid-correcting action // 2589285
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, particularly to a method for producing an agent possessing lipid-corrective action. Method for preparing agent possessing lipid-corrective action, involving extraction of phospholipids from Baikal seal liver, obtaining a concentrate of polyunsaturated fatty acids from Baikal seal fat by complex formation of free fatty acids and urea, dissolution of mixture of obtained phospholipids and concentrate of polyunsaturated fatty acids in an organic solvent with an antioxidant α-tocopherol, obtained mixture is dried in a rotary evaporator under vacuum until a thin film of lipids forms, buffer solution is then added, mixture is shaken until a homogeneous suspension forms, suspension is extruded through polycarbonate membrane.EFFECT: method described above enables to obtain an agent possessing marked lipid-corrective and antioxidant action.1 cl, 5 tbl

Agent with liposomes containing glutamic acid and propolis extract, exhibiting nootropic activity // 2589280
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, specifically to an agent possessing nootropic activity. Agent possessing nootropic activity contains glutamic acid, 10 % alcohol extract of propolis, polyethylene glycol (PEG), active substances are included into liposomes, obtained by mixing egg lecithin and PEG 2000, and hydration, then liposomes are enclosed in capsules for oral administration.EFFECT: agent described above possesses pronounced nootropic action.3 cl, 6 tbl, 4 ex

Agent with liposomes containing nicotinic acid and propolis extract having detoxification and antioxidant activity // 2585099
FIELD: chemistry.SUBSTANCE: invention relates to an agent possessing detoxification and antioxidant activity. Agent contains nicotinic acid and 10% alcohol extract of propolis, included in liposomes. Said liposomes are obtained by mixing at 40°C egg lecithin and cholesterol, taken in ratio 1:0.2, followed by hydrating with solution of sucrose. Liposomes are enclosed in capsules for oral administration in following ratio of components of liposomes per 1 capsule: 0.2 g nicotinic acid, 0.2 g of 10 % alcohol extract of propolis, 0.22 g of mixture of lecithin and cholesterol 1:0.2, hydrated with 0.5 % sucrose solution.EFFECT: invention is characterised by high bioavailability and marked prolonged action, providing maximum delivery of active substances of gastrointestinal tract in blood flow.3 cl, 5 tbl, 7 ex
ethod of producing liposome with encapsulated doxycycline hydrochloride and surface localised monoclonal antibodies // 2582969
FIELD: medicine.SUBSTANCE: invention refers to medicine, more specifically to creation of new liposomal forms of combined antibacterial preparations for treating extremely dangerous infectious diseases. Invention represents method of producing liposomes with encapsulated doxycycline hydrochloride and surface localised monoclonal antibodies, including creation of emulsion of lipids and antibacterial preparation and subsequent production of liposomes, characterised by that for increasing number of encapsulated antibiotic and additional immobilisation on surface of liposomes monoclonal antibodies, batch in 63.3 mg mixture of lipids phosphatidylcholine, cholesterol in ratio of 7:3 is dissolved in 4.3 ml of chloroform and mixed with 100 mg of antibiotic dissolved in 0.01 M of phosphate buffer with pH 7.2 in volume of 1.5 ml, treated in rotary mixer with power of 500 W at 15,000 rpm for 3 minutes until formation of emulsion, completely removed organic solvent in rotary evaporator, produced gel added with 5 ml of 0.01 M of phosphate buffer with of pH 7.2 and thoroughly stirred in flask in rotary evaporator, separating non-included antibiotics is carried out by centrifugation at 20000 rpm for 1 h in centrifuge, percentage of doxycycline immobilisation is determined by serial dilutions, at that, it amounted to 70 %, dimensions of liposomal preparation in electron microscopy study achieved from 600 to 800 nm, degree of oxidation of lipids membrane liposomes is 0.8 ± 0.02 units, that is followed by immobilising of immunoglobulins at outer membrane of liposomes, and obtained preparation is used for treating acute experimental melioidosis in laboratory animals. Production of emulsion in rotary mixer allows excluding toxic effect of titanium ions, reduced processing time and improving encapsulation of doxycycline hydrochloride for up to 70 %. Change in mode of immunoglobulin introduction in reaction mixture increases percentage of immobilisation on outer membrane of liposomes from 17 % to 30.9 %.EFFECT: produced liposomes provide 80% survival rate of laboratory animals with acute experimental melioidosis.3 cl, 1 tbl, 2 ex
Pharmaceutical composition // 2582916
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics and medicine and concerns an antigen structure and pharmaceutical composition containing it, used for therapeutic and diagnostic application in treating diseases and disorders caused by or associated with neurofibrillar plexuses. Particularly, the claim describes a pharmaceutical composition containing an antigen peptide, preferentially an antigen phosphorylated peptide simulating a primary pathological phosphor-epitope of tau-protein applicable for therapeutic and diagnostic application for treating taupathies, including Alzheimer disease.EFFECT: group of inventions provides producing a high-specific immune response in the body and makes it possible to prevent or relieve taupathies or taupathy-related diseases.34 cl, 11 ex, 15 tbl, 37 dwg

Lipids suitable for liposomal delivery of rna encoding protein // 2577983
FIELD: bioengineering.SUBSTANCE: group of inventions is described, it includes liposome for RNA delivery for in vivo expression, in it RNA is encapsulated, it encodes the targeted polypeptide, pharmaceutical composition to increase the immune reaction of vertebrate, the composition contains the above said liposome, methods of the increased protective immunological response of the vertebrate.EFFECT: invention expends nomenclature of methods of the RNA delivery.11 cl, 14 dwg, 31 tbl, 8 ex

Liposomal composition and method of obtaining thereof // 2577683
FIELD: medicine.SUBSTANCE: invention relates to medicine and consists in liposomal composition for delayed release of medication, including first liposome, which contains external membrane, consisting of multilayered lipid bilayer; and multitude of second liposomes, located in internal area of first liposome, determined by external membrane of first liposome, where each of second liposomes has external membrane, consisting of multilayered lipid bilayer, where liposomal composition has internal areas of second liposomes, each of which is determined by external membrane of each of second liposomes, with ionic gradient formed at least between each of internal areas of second liposomes and external medium of first liposome. Invention also deals with method of obtaining liposomal composition.EFFECT: delayed release of medication, which can suppress pain, persisting for 5-7 days after operation.8 cl, 5 dwg, 7 tbl, 15 ex

Lipid bilayer carrier for medicinal and imaging agents // 2577291
FIELD: medicine, pharmaceutics.SUBSTANCE: disclosed are medicinal and/or MR imaging agent carriers having a lipid bilayer coating containing a phospholipid with two end alkyl chains; one represents a short chain having a chain length of seven carbon atoms at most, the other one is a long chain and has a chain length making fifteen to thirty carbon atoms. Mixed long-/short-chain phospholipids are used to adjust the release properties of the carrier. Preferential phospholipids are phosphatidylcholines.EFFECT: producing the new compounds.13 cl, 9 dwg, 2 tbl, 5 ex

Virus-like particles (vlp) of rabies virus glycoprotein // 2575800
FIELD: medicine, pharmaceutics.SUBSTANCE: presented invention refers to biotechnology, namely a virus-like particle (VLP) applicable in vaccines or antigenic compositions for treating or preventing rabies virus (RV) infection, as well as methods for producing and using them. The virus-like particle contains one or more RV glycoproteins (G proteins), wherein G proteins are presented in the form of a micella and form a trimmer, and wherein the above micelle contains the detergent nonylphenol ethoxylate 9 (NP-9).EFFECT: presented invention enables the high-effectiveness treatment or prevention of the rabies virus infection.21 cl, 6 dwg, 2 tbl, 5 ex
Liposome having inner aqueous phase and containing sulphobutyl ester cyclodextrin salt // 2575793
FIELD: medicine.SUBSTANCE: invention refers to medicine and consists in a liposome containing a bilayer membrane and inner aqueous phase. The inner aqueous phase contains sulphobutyl ester cyclodextrin salt formed by sulphobutyl ester cyclodextrin with one or more of ammonium hydroxide, triethylamine and triethanolamine and an active substance specified in vinorelbine, vincristine, topotecan and irinotecan. The invention also refers to a method for producing the above liposome and a liposomal pharmaceutical agent containing the above liposome.EFFECT: controlling the active substance release from the liposome.8 cl, 10 ex, 8 tbl

Liposomal compositions applicable for drug delivery // 2574926
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmacology and medicine and concerns a composition representing a liposome in a medium having an internal cavity separated from the medium by means of a membrane comprising one or more lipids with the internal cavity of the liposome comprising a cationic antineoplastic therapeutic agent, as well as polyol or sugar polyanion-exchanged by means of at least two high-anionic functional groups; sugar represents monosaccharide or disaccharide, wherein the cationic agent and polyanion-exchanged polyol or polyanion-exchanged sugar are presented in the form of an acid or salt, as well as contained inside the liposome, wherein the composition represents a dosage form for parenteral administration, as well as concerns a method for encapsulating the cationic antineoplastic therapeutic agent in the liposome.EFFECT: group of inventions provides the high-load effectiveness delivery of therapeutic agents to a site, wherein a pathological process is localised.66 cl, 74 ex, 40 tbl, 47 dwg

Lipid particles containing nucleic acids and related methods // 2573409
FIELD: chemistry.SUBSTANCE: group of inventions relates to biochemistry. Claimed are: lipid particle for delivery of nucleic acid (versions), method of introducing nucleic acid in cell, method of producing lipid particles, which include nucleic acid. Lipid particle contains core, consisting of nucleic acid and cation lipid, and secondary lipids, surrounding said core. In other version lipid particle contains core, consisting of nucleic acid, cation lipid and secondary lipids, and secondary lipids, surrounding said core. Method of introduction of nucleic acid into cell includes bringing cell in contact with said lipid particles. Method of producing lipid particles, containing nucleic acid, includes introduction of first flow, which contains nucleic acid, and introduction of second flow, which contains substances, forming lipid particle, into device providing flowing of first and second flows, flowing first and second flows from first part of device into second part of device, mixing flows in second part of device to provide third flow, containing lipid particles.EFFECT: inventions provide improvement of lipid particles, containing therapeutic substance, increased efficiency of encapsulation of nucleic acids into lipid particle.18 cl, 33 dwg, 1 tbl, 5 ex

Parenteral formulations of elacytarabine derivatives // 2571283
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to parenteral formulations for administering certain derivatives formed by 1-β-D-arabinofuranosylcytosine (cytarabine) and saturated and monounsaturated long-chain fatty acids (elacytarabine).EFFECT: present invention refers to the parenteral pharmaceutical composition enabling administering therapeutically effective doses of the above derivatives, which increases patient's compliance with cancer treatment, as well as to a method for producing the same.15 cl, 6 ex, 5 tbl, 2 dwg

Long-acting controlled release liposomal composition and method for producing it // 2571077
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics. What is described is a liposomal composition produced by mixing a water-soluble organic solution with a solution of first aqueous phase, and producing an emulsion. The water-soluble organic solution contains phospholipid and cholesterol. That is followed by replacing an outer emulsion with a solution representing a second aqueous phase. That makes produce an ion gradient between the aqueous phase of the inside and that of the outside of a liposomal membrane. The produced liposome is characterised by an average particle diameter in terms of an outer diameter making from 2.5 mcm to 12 mcm, and a 12-35-layer structure. What is described is a prolonged- and controlled-release liposomal preparation containing a therapeutic agent, as well as a kit of the prolonged- and controlled-release liposomal preparation.EFFECT: controlled release with the effective concentration of the medicinal product maintained for four days.6 cl, 6 dwg, 11 tbl, 18 ex
ethod of two-phase obtaining of liposomes and methods of their application in production of diagnostic reagents // 2567746
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to the field of biotechnology. Claimed are: a method of two-phase obtaining of liposomes, a method of obtaining a diagnostic reagent for the determination of the prothrombin time and a method of obtaining a diagnostic reagent for the determination of the thromboplastin time. The method of two-phase obtaining of liposomes includes obtaining a liposome emulsion. The liposome emulsion with the concentration of lipids in it of 0.5-1.5 g/ml is obtained by mechanic mixing. The method of obtaining the diagnostic reagent for the determination of the prothrombin time includes application of liposome by the said method. The liposome emulsion and the natural or recombinant tissue factor are mixed in a proportion of 2:1 in a buffer medium. The method of obtaining the diagnostic reagent for the determination of the thromboplastin time includes application of liposome by the said method. The liposome emulsion and a negatively charged active component are mixed in a proportion of 1:1 in a buffer medium.EFFECT: technical simplification of the method for obtaining liposome emulsions, simplicity of realisation of the methods for obtaining diagnostic objects is provided.7 cl, 13 ex

Conjugates for administering biologically active compounds // 2567667
FIELD: chemistry.SUBSTANCE: invention relates to biotechnology and particularly to conjugates of Apo A with therapeutic polypeptides, and can be used in medicine. A conjugate is obtained, having an Apo A-I molecule or a functionally equivalent version thereof, such as Apo A-IV or Apo A-V, covalently bonded to the polypeptide of therapeutic interest, which is selected from interferon, TGF-beta inhibitor P144 or P17, IL-15, cardiotrophin-1, porphobilinogen deaminase, insulin and factor VII.EFFECT: obtained conjugate prolongs the half-life of a therapeutic polypeptide administered to an individual, and also enables delivery thereof to those tissues having specific binding sites for the Apo A molecule.32 cl, 16 dwg, 1 tbl, 15 ex

Food components delivery system // 2566984
FIELD: food industry.SUBSTANCE: proposed invention relates to food industry, in particular, to manufacture of taste-and-flavour compounds delivery systems. The delivery system has a structure containing surfactant aggregates; the delivery system contains a surfactant system chosen from the group consisting of non-ionic and zwitterionic surfactants (such surfactant contained in an amount equal to and exceeding its critical micelle formation concentration), a hydrophilic phase represented by water and/or water solvent in an amount of 10 wt % or more relative to the total weight of delivery system and 00001 - 5 wt % relative to the total weight of the system for delivery of the compound with the structure (Formula 1)or its salt and/or solvates ("Compound 1") where at least a part of Compound 1 is encapsulated in the surfactant aggregates.EFFECT: proposed delivery system ensures protection of Structure 1 compound against environmental effects.16 cl, 12 tbl, 9 ex

Preparation with liposomes, containing succinic acid and propolis extract, possessing disintoxication and antioxidant activity // 2561591
FIELD: pharmacology.SUBSTANCE: capsules for per oral introduction contain liposomes, obtained at mixing of egg lecithin and cholesterol. Liposomes contain succinic acid and 10% alcohol extract of propolis as active substances, saccharose and water purified with the following component ratio, a g per 1 capsule: succinic acid - 0.1; alcohol propolis extract 10% - 0.2; 0.2% saccharose water solution - 0.02, suspension of phosphatidylcholine and cholesterol in ratio 1:0.2 - 0.3, as auxiliary substances.EFFECT: preparation has disintoxicating and antioxidant, as well as antiedematous, spasmolytic, anti-inflammatory, regenerating and antibacterial action, uniform release of active substances and expressed prolonged action, is convenient for independent application by patients.3 cl, 5 tbl, 6 ex
Injectable dosage form of oligopeptide preparation for treating multiple sclerosis and method for producing it // 2561582
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics and concerns an injectable dosage form of oligopeptides for treating multiple sclerosis. The injectable dosage form contains oligopeptides GGDRGAPKRGSGKDSHH; GFGYGGRASDYKSAHK; QGTLSKIFKLGGRDSRSGSPMARR, enclosed into liposomes, consisting of mixed mannosyalised dipalmitoyl phosphatidyl ethanolamine, 2,3-dipalmitoyl-sn-glycero-1-phosphatidylcholine, as well as lactose as a cryoprotector and alpha tocopherol as an antioxidant, as well as a method for preparing it.EFFECT: group of invention provides enhancing the therapeutic effect.2 cl, 2 ex, 1 tbl

Agent for treating myelofibrosis // 2557997
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a substance-delivering carrier for the substance delivery to a bone marrow cell producing an extracellular matrix containing retinoid as a delivering agent, wherein the substance is a therapeutic agent, which inhibits the beginning, progression and/or recurrence of myelofibrosis.EFFECT: invention provides the effective inhibition of the beginning, progression and recurrence of myelofibrosis.10 cl, 14 dwg, 8 ex

Encapsulated lyposomal antiviral agent based on human interferon alpha-2b for vaginal application // 2552851
FIELD: medicine.SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.2 cl, 3 dwg, 6 tbl, 6 ex

Therapeutic agent applicable in pulmonary fibrosis // 2547571
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for reducing extracellular matrix producing cells in lungs or suppressing an increase of the extracellular matrix producing cells in lungs, involving administering into an individual a composition containing (i) a carrier containing retinoid as a targeting agent, and (ii) a pro-drug specified in a group consisting of siRNA, RNA enzyme, anti-sense nucleic acid and DNA/RNA chimeric polynucleotide, which is targeted on HSP47, and vectors expressing said siRNA, RNA enzyme, anti-sense nucleic acid and/or DNA/RNA chimeric polynucleotide.EFFECT: invention provides using retinoic acid as a targeting agent for the drug delivery to the extracellular matrix producing cells in the lungs.8 cl, 6 dwg, 3 ex

Stable crystalline dopc modifications // 2543046
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to novel crystalline modification (R)-DOPC, which can be applied in pharmaceutical industry. Claimed is novel crystalline form of DOPC and method of its obtaining, as well as its application as component in obtaining medications. Claimed method consists in the fact that crystallisation of (R)-DOPC is carried out in aprotic solvent.EFFECT: claimed crystalline form of DOPC is characterised by improved stability.14 cl, 5 ex, 2 tbl, 11 dwg

Compositions and methods of treating bladder cancer // 2542449
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a pharmaceutical composition for treating bladder cancer. The above composition contains an effective amount of valrubicin and dimethyl sulphoxide, as well as polyethoxylated castor oil or one or more substances specified in trimethyl chitosan, mono-N-carboxymethyl chitosan, N-diethylmethyl chitosan, sodium caprylate, cytochalasin B, IL-1, polycarbophil, Carbopol 934P, N-sulphate-N,O-carboxymethyl chitosan, Zonula occludens toxin, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine, and represents a dosage form for intra-bladder administration by instillation. The invention also refers to liposomal pharmaceutical compositions containing valrubicin, and methods of treating bladder cancer involving administering the above compositions.EFFECT: invention reduces bladder irritation and increases the clinical effectiveness in bladder cancer.12 cl, 3 dwg, 3 tbl, 1 ex

ethod and composition for treating cancer // 2541100
FIELD: medicine, pharmaceutics.SUBSTANCE: group of invention refers to medicine, namely to oncology, and can be used in treating cancer in a patient. The method involves administering at least one encapsulated chemotherapeutic agent, and at least one amphiphilic block copolymer in this patient. What is also presented is a composition, a kit for treating cancer in the patient and using the amphiphilic block copolymer.EFFECT: group of inventions provides potentiating the encapsulated chemotherapeutic agent by stimulating the active chemotherapeutic agent release from liposomes by the use of the amphiphilic block copolymer, which is poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer, in the composition.10 cl, 11 dwg, 3 tbl, 4 ex

ethod of treating pulmonary diseases with liposomal amikacin formulations // 2537238
FIELD: medicine.SUBSTANCE: inventions refers to medicine, namely to pulmonology, and can be used for treating a pulmonary disorder in a patient. That is ensured by administering an effective dose of the nebulised liposomal amikacin formulation of 100 to 2,500 mg daily within the cycle of treatment, which involves the period of administration from 15 to 75 days and the following withdrawal period from 15 to 75 days. The cycle of treatment repeats at least twice.EFFECT: invention provides improving the pulmonary function, which is supported for at least 15 days after the termination of treatment, and increasing the one-second forced expiratory volume (FEV1).28 cl, 16 tbl, 11 dwg, 3 ex
Pharmaceutical composition containing lysine and enzymes: lysozyme, deoxyribonuclease and/or peroxidase for external treatment and prevention of infections caused by type 1, 2 herpes viruses, and bacterial complications caused by herpetic infection // 2535053
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for the external treatment and prevention of infections caused by the type 1, 2 herpes virus and bacterial complications caused by the herpetic infection, containing lysozyme, peroxidase, povyargol as active ingredients, escin and glycyrrhizinic acid or its salts as anti-inflammatory ingredients, liposomes on the basis of high-active hydrated lecithin in a combination with cholesterol as carriers and pharmaceutically acceptable carriers and excipients, with the ingredients of the composition being taken in certain proportions, wt %.EFFECT: invention provides extending the range of products for treating and preventing the infections caused by type 1, 2 herpes virus and bacterial complications caused by the herpetic infection.4 ex, 1 tbl

Pharmaceutical composition containing docosahexaenoic acid ester for parenteral administration // 2535029
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to pharmaceutics and represents a pharmaceutical composition for parenteral administration containing sub-micron particles of dosocahexaenoic acid ester dispersed in a water phase with the use of mixture of at least two surfactants specified in a) at least one fatty acid polyoxyethylene ester and b) at least one phospholipide derivative, as well as a method for preparing the above pharmaceutical composition.EFFECT: invention provides higher pharmacological activity.14 cl, 3 dwg, 3 tbl, 2 ex

Liposome suspension stabiliser and method for production thereof // 2529179
FIELD: chemistry.SUBSTANCE: stabiliser includes modified chitosan which is obtained by modifying chitosan particles located in an emulsion of an organic solvent - water, with pH 6.0-6.5, by first reacting a mixture consisting of a carboxylic acid in an organic solvent and a condensing agent, and then with an organic base, wherein the carboxylic acid used is either palmitic acid or stearic acid or dodecanoic acid, the condensing agent used is a mixture of hydroxysuccinimide and an aliphatic carbodiimide or formaldehyde and an aliphatic isocyanide, and the organic base used is triethylamine.EFFECT: effective liposome composition stabiliser which can be obtained using a simple method.8 cl, 3 tbl, 5 ex, 7 dwg

Drug carrier for contrast enhancement in mrt // 2528104
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a carrier applicable for the local drug delivery. A drug is enclosed in a carrier, and the carrier comprises a coating able to release an enclosed drug as a result of a local stimulus. The coating additionally surrounds the contrast agent MR 19F which changes its detectability after being released from the carrier. The invention refers to a method for the drug delivery to an MRT-controlled individual, wherein the method involves administering the above carrier into the individual enabling the carrier releasing the drug, and forming MR 19F images with the use of a contrast produced by the contrast agent MR 19F.EFFECT: invention enables monitoring the beginning of the drug release from the carrier.18 cl, 11 dwg, 2 tbl, 2 ex

Irinotecan liposomes or its salts, method for preparing them // 2526114
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and concerns irinotecan liposomes or its hydrochloride containing irinotecan or its hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of cholesterol to neutral phospholipid makes 1:3-5, and a method for preparing them.EFFECT: liposomes have higher stability.15 cl, 3 dwg, 10 tbl, 10 ex
 
2551355.
Up!